2021-08-17FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumorsTrial GARNETDrug Jemperli (dostarlimab-gxly) · Anti-PD-1 antibodyConditionOther solid neoplasm
2021-07-26FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancerTrial MK-3475-522Drug Keytruda (pembrolizumab) · Anti-PD-1 antibodyConditionBreast
2020-11-13FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancerTrial KEYNOTE-355Drug KEYTRUDA (pembrolizumab) · Anti-PD-1 antibodyConditionBreast
2020-06-16FDA approves pembrolizumab for adults and children with TMB-H solid tumorsTrial KEYNOTE 158Drug KEYTRUDA (pembrolizumab) · Anti-PD-1 antibodyConditionOther solid neoplasm